Your browser doesn't support javascript.
loading
Cystic fibrosis patient characteristics and healthcare resource utilization in Finland using linked registries.
Malmivaara, Kirsi; Pölkki, Mari; Prami, Tuire; Raittinen, Paavo; Heikkilä, Eija; Aalto, Antti; Dunder, Teija; Elenius, Varpu; Sandström, Kristina; McGarry, Lisa J.
Afiliação
  • Malmivaara K; Helsinki University Hospital, Helsinki, Finland.
  • Pölkki M; Oriola, Espoo, Finland.
  • Prami T; Oriola, Espoo, Finland.
  • Raittinen P; Oriola, Espoo, Finland.
  • Heikkilä E; Oriola, Espoo, Finland.
  • Aalto A; Swell Scientific, Helsinki, Finland.
  • Dunder T; Oulu University Hospital, Oulu, Finland.
  • Elenius V; Turku University Hospital, Turku, Finland.
  • Sandström K; Vertex Pharmaceuticals AB, Stockholm, Sweden.
  • McGarry LJ; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
Heliyon ; 10(13): e33439, 2024 Jul 15.
Article em En | MEDLINE | ID: mdl-39040318
ABSTRACT

Background:

Knowledge of prevalence and epidemiology of cystic fibrosis (CF) and healthcare resource use among Finnish people with CF is incomplete.

Methods:

We conducted a population-based matched cohort study using retrospective real-world data from linked Finnish national registries. Electronic healthcare data and drug purchases of 102 people with CF were analyzed between January 2015 and December 2019 (follow-up). A 5-fold control population was matched by sex, age, and place of residence. Comorbidities and medication use that occurred at any time during follow-up were assessed; annual rates of hospital service use were adjusted for follow-up.

Results:

The prevalence of CF in Finland was 1.85 per 100,000. Median age at diagnosis was 1 year, with 60 % diagnosed at age <2 years and 80 % at age <10 years. Median age at death in people with CF was 31.4 years (n < 5); no controls died. The most common comorbidities included chronic sinusitis (39.2 %), pneumonia (38.2 %), diabetes (20.6 %), and nasal polyps (18.6 %). The most purchased medications were antibiotics (99.0 %) and pancreatic enzymes (84.3 %). The annualized rate of hospital visits was higher in people with CF vs controls (outpatient mean [SD], 17.4 [14.5] vs 0.9 [3.3]; median, 13.6 vs 0.4, respectively; inpatient mean [SD], 1.0 [1.66] vs 0.03 [0.14]; median, 0.34 vs 0, respectively).

Conclusions:

The prevalence of CF in Finland is remarkably low, likely reflecting unique population characteristics and, in part, delayed diagnosis. Antibiotic use is frequent among Finnish people with CF. Inpatient hospital visits are >30 times higher in people with CF than matched controls.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Heliyon Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Finlândia

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Heliyon Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Finlândia